Investment Bank Initiates Overweight Rating For Biotech Firm
Barclays Initiates Coverage On Geron Corporation with Overweight Rating, Announces Price Target of $9.
Disclaimer: The following article is for informational purposes only and should not be construed as financial advice. Any investment carries risk, and readers are encouraged to consult with a financial advisor before making any investment decisions.
As an investor it's important to stay updated with major news. Get real-time stock…